Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Parmax Pharma Ltd - 540359 - Compliance Certificate Pursuant To Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Year Ended On 31St March, 2019.

 Dear Sir/Madam, Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that all activities in relation to both physical and electronic share transfer facility are maintained during the period of 1st October 2018 to 31st March, 2019 (both days inclusive) by the Company''s Registrar and Share Transfer Agent, i.e. M/s Purva Sharegistry India Pvt. Ltd., having its Office at Unit no. 9, Shiv Shakti Ind. Estt. J .R. Boricha Marg, Lower Parel (E), Mumbai 400 011. Further, we confirm that M/s Purva Sharegistry India Pvt. Ltd. is registered as Permanent Category- I Registrar and Transfer Agent with the Securities and Exchange Board of India (SEBI Registration no. INR000001112). Kindly take the above information on your records.
11-04-2019
Bigul

Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended March 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH J VORADesignation :- Company Secretary and Compliance Officer
09-04-2019
Bigul

Parmax Pharma Ltd - 540359 - Closure of Trading Window

 This is to inform you that under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and as per the Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities, and pursuant to BSE Circular Ref. LIST / COMP / 01/ 2019-20 Dated 2nd April, 2019 the trading window for dealing in securities of the Company shall remain closed from 1st April, 2019 and will re open after 48 hours of declaration of financial results for the Quarter and Year ended March 31, 2019. The Communication has been informed to all "Directors, concerned persons/ employees/ insiders" of the company as defined in the code. This is for your information and record please. Thanking You,
03-04-2019
Bigul

Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that, Mr. Keyur Vora, Chief Financial Officer, informed the Board of Directors, at their meeting held today, of his decision to step down from the post of Chief Financial Officer with effective from 30th April, 2019. Mr. Keyur Vora expressed his gratitude to each member of Board, for their valuable guidance and contribution during his tenure. He placed on record his deep appreciation to the Parmax leadership team, management, employees and business partners for their continued trust and confidence in him. Members of the Board placed on record their appreciation for significant contributions made by Mr. Keyur Vora to Parmax Pharma. The Board wished him continued success and very best for future endeavors. The Board is in process of identification of suitable successor for the role of Chief Financial Officer of Company. Kindly take note of the same in your records. Thanking You,
18-03-2019
Bigul

Parmax Pharma Ltd - 540359 - Outcome of Board Meeting

 This is to notify that we hereby submitting the outcome of the Meeting of the Board of Directors held today, 17th March, 2019 at 12:00 p.m. at the Registered Office of the Company and was concluded at 7:30 p.m.: 1.Upon recommendation of Nomination and Remuneration Committee and subject to approval of Shareholders in General Meeting the Board has considered and approved the revision in remuneration of Mr. Alkesh M. Gopani, Managing Director w.e.f 1st April, 2019. 2.Upon recommendation of Nomination and Remuneration Committee and subject to approval of Shareholders in General Meeting the Board has considered and approved the revision in remuneration of Mr. Alkesh R. Gosalia, Managing Director (Finance and Operations) w.e.f. 1st April, 2019. 3.Upon recommendation of Nomination and Remuneration Committee and subject to approval of Shareholders in General Meeting the Board has considered and approved the revision in remuneration of Mr. Umang Alkesh Gosalia Whole-time Director w.e.f. 1st April, 2019. 4.Mr. Keyur Vora Chief Financial Officer informed the Board of Directors, at their meeting held today of his decision to step down from the post of Chief Financial Officer of the Company w.e.f. 30th April, 2019. Please take the same on record.
18-03-2019
Bigul

Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Mr. Alkesh M. Gopani, Managing Director Subject To Approval Of Shareholders In General Meeting. 2. To Consider And Approve Revision In Remuneration Of Mr. Alkesh R. Gosalia, Managing Director (Finance And Operations) Subject To Approval Of Shareholders In General Meeting. 3. To Consider And Approve Revision In Remuneration Of Mr. Umang Gosalia, Whole-Time Director Subject To Approval Of Shareholders In General Meeting. 4. To Review Current Business Operations Of The Company And Discuss The Future Business Plans For Financial Year 2019-20. 5. Any Other Business With The Permission Of The Chair.

 Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/03/2019 ,inter alia, to consider and approve This is to notify that meeting of the Board of Directors of the Company is scheduled to be held on Sunday 17th March, 2019 at 12:00 p.m. at the Registered Office of the Company to transact the following businesses: 1. To consider and approve revision in remuneration of Mr. Alkesh M. Gopani, Managing Director subject to approval of Shareholders in General Meeting. 2. To consider and approve revision in remuneration of Mr. Alkesh R. Gosalia, Managing Director (Finance and Operations) subject to approval of Shareholders in General Meeting. 3. To consider and approve revision in remuneration of Mr. Umang Gosalia, Whole-time Director subject to approval of Shareholders in General Meeting. 4. To review current business operations of the Company and discuss the future business plans for Financial Year 2019-20. 5. Any other Business with the permission of the Chair. Please take the same on record. Thanking You, Yours Faithfully.
09-03-2019
Bigul

Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In terms of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a copy of the advertisement clipping of Extract of Standalone Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2018 published in Financial Express (English daily) and Financial Express (Gujarati daily) dated 16th February, 2019 which were approved at the Board Meeting of the Company held on Thursday, the 14th day of February, 2019. Thanking You,
18-02-2019
Bigul

Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Sub: Intimation of change in the designation of Directors. Pursuant to Regulation 30 of SEBI {LODR) Regulations, 2015, we write to inform you that the Board of Directors of the Company in its meeting held on 14th February, 2019, pursuant to the recommendation of the Nomination & Remuneration Committee, Board of Directors have considered and approved to re-designate Shri Alkesh Gosalia from Director to Managing Director (Finance and Operations) of the Company with effect from 15th February, 2019. Further Board of Directors of the Company in its meeting held on 14th February, 2019, pursuant to the recommendation of the Nomination & Remuneration Committee, Board of Directors have considered and approved to re-designate Shri Umang Gosalia from Director to Whole-time Director of the Company with effect from 15th February, 2019.
15-02-2019
Bigul

Parmax Pharma Ltd - 540359 - 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2018 2. Limited Review Report For The Quarter And Nine Months Ended 31St December, 2018

 Dear Sirs, This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 14th February, 2019, inter-alia, considered and approved the Unaudited Financial Results for quarter and Nine Months ended 31st December, 2018. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 31st December, 2018, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. A copy thereof has also been sent for publication as per the requirements. The meeting commenced at 1:00 pm. and concluded 4:30 pm.
14-02-2019
Bigul

Parmax Pharma Ltd - 540359 - Outcome of Board Meeting

 Dear Sirs, This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 14th February, 2019, inter-alia, considered and approved the Unaudited Financial Results for quarter and Nine Months ended 31st December, 2018. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 31st December, 2018, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. A copy thereof has also been sent for publication as per the requirements. The meeting commenced at 1:00 pm. and concluded 4:30 pm. We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter and Nine Months ended 31st December, 2018 and Board has also taken on record their Limited Review Report on said Results.
14-02-2019
Next Page
Close

Let's Open Free Demat Account